Biallelic loss, loss of heterozygosity, point mutations and epigenetic silencing of the B2M gene that result in MHCI deficiency are frequently encountered across several human cancers and are thought to be contributory to ICI resistance [10–14]. This evidence concerns the gene B2M and cancer.